Novartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients

Novartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients

Sep 17, 2016
Source URL: https://qa1.novartis.us/news/media-releases/novartis-baf312-reduced-risk-disability-progression-pivotal-phase-iii-study-secondary-progressive-ms-patients-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/novartis-baf312-reduced-risk-disability-progression-pivotal-phase-iii-study-secondary-progressive-ms-patients-0